HIV/AIDS
Conditions
Interventions
experimental group:Biktarvy is taken orally once a day.
Control group:TDF+FTC+DTG/RAL
Sponsors
Guiyang public health treatment center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age =18, male or female; 2.HIV rapid test is negative; 3. Willing to sign a written informed consent form; 4. Willing and able to complete all research follow-ups; 5. Willing to participate in all research activities; 6. Fertility women: they are willing to take contraceptive measures during the period of taking the research drugs; 7. After HIV-1 sexual exposure, you can take the first dose of study drug within 72 hours.
Exclusion criteria
Exclusion criteria: 1. The known exposure source is HIV negative; 2. Known intolerance or allergy to drugs or excipients used in this study; 3. In the opinion of the researcher, there may be any potential violation of test compliance or any other situation that affects the evaluation of safety and effectiveness; 4.The exposure time exceeds 72h.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of subjects who completed 28 days of prophylactic medication; | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of adverse events (AE) and serious adverse events (SAE);Adherence to the regimen;HIV sero-conversion at 28 days and 12 weeks after exposure; | — |
Countries
China
Contacts
Public ContactHai Long
Guiyang public health treatment center
Outcome results
None listed